A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

Cancer

Volumn 118, Issue 14, 2012, Pages 3556-3564

  Khoury, Hanna Jean ^a   Garcia Manero, Guillermo ^b   Borthakur, Gautam ^b   Kadia, Tapan ^b   Foudray, Maria Cielo ^b   Arellano, Martha ^a   Langston, Amelia ^a   Bethelmie Bryan, Beverly ^a   Rush, Selena ^c   Litwiler, Kevin ^c   Karan, Sharon ^c   Simmons, Heidi ^c   Marcus, Adam I ^a   Ptaszynski, Mieke ^c   Kantarjian, Hagop ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ARRAY BIOPHARMA INC   (United States)

Author keywords

advanced myeloid leukemia; ARRY 520; kinesin spindle protein inhibitor; maximum tolerated dose; myelodysplastic syndrome; phase 1; relapsed

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ANTINEOPLASTIC AGENT; ARRY 520; KINESIN; KINESIN SPINDLE PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ASYMPTOMATIC DISEASE; BACTEREMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CELLULITIS; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPERPHOSPHATEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MONONUCLEAR CELL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PANCYTOPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SPINDLE CELL; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KINESIN; LEUKEMIA, MYELOID; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; RETREATMENT; THIADIAZOLES;

EID: 84863335493     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26664     Document Type: Article

References (36)

1. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896-903. (Pubitemid 24299870)
2. Glucksberg H, Cheever MA, Farewell VT, Fefer A, Sale GE, Thomas ED,. High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer. 1981; 48: 1073-1081. (Pubitemid 11052879)
3. Preisler HD, Rustum Y, Henderson ES, et al. Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood. 1979; 53: 455-464. (Pubitemid 9140401)
4. Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood. 1991; 77: 1429-1435.
5. Tricot G, Boogaerts MA, Vlietinck R, Emonds MP, Verwilghen RL,. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia. Br J Haematol. 1987; 66: 37-44. (Pubitemid 17071186)
6. Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992; 79: 313-319.
7. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood. 1992; 79: 2578-2582.
8. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL,. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993; 81: 311-318. (Pubitemid 23027144)
9. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339: 1649-1656. (Pubitemid 28550689)
10. Peterson BA, Bloomfield CD,. Long-term disease-free survival in acute nonlymphocytic leukemia. Blood. 1981; 57: 1144-1147. (Pubitemid 11050824)
11. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58: 1203-1212. (Pubitemid 12251149)
12. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD,. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983; 62: 315-319. (Pubitemid 13036080)
13. Peterson BA, Bloomfield CD,. Prolonged maintained remissions of adult acute non-lymphocytic leukaemia. Lancet. 1977; 2: 158-160. (Pubitemid 8143256)
14. Passe S, Miké V, Mertelsmann R, Gee TS, Clarkson BD,. Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up. Cancer. 1982; 50: 1462-1471. (Pubitemid 12034538)
15. Velu T, Debusscher L, Stryckmans P,. Daunorubicin in patients with relapsed and refractory acute nonlymphoblastic leukemia previously treated with anthracycline. Am J Hematol. 1988; 27: 224-225.
16. Willemze R, Zwaan FE, Colpin G, Keuning JJ,. High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol. 1982; 29: 141-146. (Pubitemid 12054533)
17. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP,. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983; 62: 361-369. (Pubitemid 13036086)
18. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP,. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol. 1985; 3: 992-997. (Pubitemid 15028571)
19. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010; 28: 3730-3738.
20. Coleman PJ, Fraley ME,. Inhibitors of the mitotic kinesin spindle protein. Expert Opin Ther Patents. 2004; 14: 1659-1667. (Pubitemid 39625099)
21. Vale RD, Milligan RA,. The way things move: looking under the hood of molecular motor proteins. Science. 2000; 288: 88-95.
22. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ,. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol. 2000; 150: 975-988.
23. Sawin KE, LeGuellec K, Philippe M, Mitchison TJ,. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature. 1992; 359: 540-543.
24. Blangy A, Lane HA, d'Hérin P, Harper M, Kress M, Nigg EA,. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995; 83: 1159-1169.
25. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res. 2004; 64: 3276-3280. (Pubitemid 38581433)
26. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ,. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999; 286: 971-974.
27. Cox CD, Breslin MJ, Mariano BJ, et al. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett. 2005; 15: 2041-2045. (Pubitemid 40445465)
28. Lobell J, Deihl R, Mahan E, et al. In vivo characterization of an inhibitor of the mitotic kinesin, KSP: pharmacodynamics, efficacy, and tolerability in xenograft tumor models [Abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 14-18, 2005; Philadelphia, PA. Abstract B189.
29. Gonzales P, Bienek A, Piazza G, et al. Breadth of anti-tumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP [Abstract]. In: Proceedings of the American Association for Cancer Research 93rd Annual Meeting; April 6-10, 2002; San Francisco, CA. Abstract 1337.
30. Johnson R, Caulder E, Inlow-Porter L, et al. A potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts [Abstract]. In: Proceedings of the American Association for Cancer Research 93rd Annual Meeting; April 6-10, 2002; San Francisco, CA. Abstract 1335.
31. Woessner R, Tunquist B, Lemieux C, et al. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res. 2009; 29: 4373-4380.
32. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425. (Pubitemid 44061337)
33. Zhang S, Schafer-Hales K, Khuri FR, Zhou W, Vertino PM, Marcus AI,. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res. 2008; 68: 740-748. (Pubitemid 351206750)
34. Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem. 2005; 280: 11569-11577. (Pubitemid 40418469)
35. Tunquist BJ, Woessner RD, Walker DH,. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther. 2010; 9: 2046-2056.
36. Gomez HL, Castaneda C, Pimentel P, et al. A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence. J Clin Oncol. 2009; 27 (suppl): 15s (abstract 1077).